Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDACAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a ...
Create apps, automate workflows, and build agents using App Builder and Workflows agents in Microsoft 365 Copilot and Copilot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback